Dyadic Announced An MoU With Bangladesh's State-Owned Pharmaceutical Company To Facilitate Biopharmaceutical Research And Biomanufacturing Capacity
Portfolio Pulse from Happy Mohamed
Dyadic International (NASDAQ:DYAI) has entered into a Memorandum of Understanding with Bangladesh's state-owned Essential Drugs Company Limited (EDCL) to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, and regulatory efforts in Bangladesh.
June 21, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dyadic's partnership with EDCL could expand its global reach and enhance its proprietary C1 protein production platform.
The partnership with EDCL demonstrates Dyadic's ability to leverage its proprietary C1 protein production platform to facilitate biomanufacturing infrastructure globally. This could lead to increased adoption of Dyadic's microbial platforms in developing and manufacturing biopharmaceutical vaccines and drugs, ultimately benefiting the company's growth and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100